The impact of SGLT2 inhibitors on uric acid levels in patients with heart failure with preserved ejection fraction: integration of mechanisms and clinical evidence. [PDF]
Front Cardiovasc MedZhang Y, Xiao X, Yan Q, Huang D, Wang W.
europepmc +1 more source
Mitochondrial Proteostasis Links Diabetes and Sarcopenia: Cross-Scale Convergence from Experimental Models to Human Multi-Omics. [PDF]
Diabetes Metab JWei S, Shin S, Ryu D, Oh CM.
europepmc +1 more source
Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review. [PDF]
Front PharmacolYang Y, Wang K.
europepmc +1 more source
Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential. [PDF]
MoleculesZieliński M +3 more
europepmc +1 more source
Effect of Baseline Values of Renal Prognosis-related Factors on Their Changes after Initiating Tofogliflozin Treatment: A Retrospective Study in Japanese Patients with Type 2 Diabetes and Renal Impairment. [PDF]
JMA JMatsumoto S +8 more
europepmc +1 more source
Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin
, 2014 openaire +1 more source
SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes. [PDF]
Eur J Clin PharmacolAli EAH +10 more
europepmc +1 more source
Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. [PDF]
Front Med (Lausanne)Yang L, Ruan J, Fang Y, Xu A.
europepmc +1 more source
Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort. [PDF]
Medicine (Baltimore)Higashikawa T +15 more
europepmc +1 more source